Literature DB >> 15223207

Renal biopsy: methods and interpretation.

Shelly L Vaden1.   

Abstract

Renal biopsy most often is indicated in the management of dogs and cats with glomerular disease or acute renal failure. Renal biopsy can readily be performed in dogs and cats via either percutaneous or surgical methods. Care should be taken to ensure that proper technique is used. When proper technique is employed and patient factors are properly addressed, renal biopsy is a relatively safe procedure that minimally affects renal function. Patients should be monitored during the post biopsy period for severe hemorrhage, the most common complication. Accurate diagnosis of glomerular disease, and therefore, accurate treatment planning,requires that the biopsy specimens not only be evaluated by light microscopy using special stains but by electron and immunofluorescent microscopy.

Entities:  

Mesh:

Year:  2004        PMID: 15223207     DOI: 10.1016/j.cvsm.2004.03.010

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  3 in total

1.  Prevalence of Glomerulopathies in Canine Mammary Carcinoma.

Authors:  Leandro Z Crivellenti; Gyl E B Silva; Sofia Borin-Crivellenti; Rachel Cianciolo; Christopher A Adin; Márcio Dantas; Denner S Dos Anjos; Mirela Tinucci-Costa; Aureo E Santana
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

2.  Renal scintigraphy as an early and efficient method for detecting loss of renal function in a cat.

Authors:  Gabriela C Schaefer; Mariana M Brose; José R Herrera Becerra; Fabíola Ps Mello; Inácio B Rovaris; Eduardo Herz Berdichevski; Márcio P Ferreira; Fernanda Va da Costa
Journal:  JFMS Open Rep       Date:  2021-12-08

3.  Glomerulotubular pathology in dogs with subclinical ehrlichiosis.

Authors:  Leandro Zuccolotto Crivellenti; Cristiane Alves Cintra; Suellen Rodrigues Maia; Gyl Eanes Barros Silva; Sofia Borin-Crivellenti; Rachel Cianciolo; Christopher A Adin; Mirela Tinucci-Costa; Caio Santos Pennacchi; Aureo Evangelista Santana
Journal:  PLoS One       Date:  2021-12-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.